Role of 53BP1 in end protection and DNA synthesis at DNA breaks.


Journal

Genes & development
ISSN: 1549-5477
Titre abrégé: Genes Dev
Pays: United States
ID NLM: 8711660

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 14 05 2021
accepted: 17 08 2021
pubmed: 11 9 2021
medline: 5 4 2022
entrez: 10 9 2021
Statut: ppublish

Résumé

Double-strand break (DSB) repair choice is greatly influenced by the initial processing of DNA ends. 53BP1 limits the formation of recombinogenic single-strand DNA (ssDNA) in BRCA1-deficient cells, leading to defects in homologous recombination (HR). However, the exact mechanisms by which 53BP1 inhibits DSB resection remain unclear. Previous studies have identified two potential pathways: protection against DNA2/EXO1 exonucleases presumably through the Shieldin (SHLD) complex binding to ssDNA, and localized DNA synthesis through the CTC1-STN1-TEN1 (CST) and DNA polymerase α (Polα) to counteract resection. Using a combinatorial approach of END-seq, SAR-seq, and RPA ChIP-seq, we directly assessed the extent of resection, DNA synthesis, and ssDNA, respectively, at restriction enzyme-induced DSBs. We show that, in the presence of 53BP1, Polα-dependent DNA synthesis reduces the fraction of resected DSBs and the resection lengths in G0/G1, supporting a previous model that fill-in synthesis can limit the extent of resection. However, in the absence of 53BP1, Polα activity is sustained on ssDNA yet does not substantially counter resection. In contrast, EXO1 nuclease activity is essential for hyperresection in the absence of 53BP1. Thus, Polα-mediated fill-in partially limits resection in the presence of 53BP1 but cannot counter extensive hyperresection due to the loss of 53BP1 exonuclease blockade. These data provide the first nucleotide mapping of DNA synthesis at resected DSBs and provide insight into the relationship between fill-in polymerases and resection exonucleases.

Identifiants

pubmed: 34503990
pii: gad.348667.121
doi: 10.1101/gad.348667.121
pmc: PMC8494207
doi:

Substances chimiques

DNA, Single-Stranded 0
Tumor Suppressor p53-Binding Protein 1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1356-1367

Subventions

Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA085344
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233664
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211397
Pays : United States

Informations de copyright

© 2021 Paiano et al.; Published by Cold Spring Harbor Laboratory Press.

Références

Mol Cell. 2016 Sep 1;63(5):898-911
pubmed: 27477910
Nature. 2010 Sep 2;467(7311):112-6
pubmed: 20811461
Nat Rev Mol Cell Biol. 2020 Dec;21(12):765-781
pubmed: 33077885
Nat Struct Mol Biol. 2017 Apr;24(4):353-361
pubmed: 28263325
EMBO J. 2018 Jun 15;37(12):
pubmed: 29789392
Mol Cell. 2019 Jul 11;75(1):145-153.e5
pubmed: 31153714
Cell Rep. 2018 May 15;23(7):2107-2118
pubmed: 29768208
J Biol Chem. 2001 May 25;276(21):18235-42
pubmed: 11278525
Nat Cell Biol. 2018 Aug;20(8):954-965
pubmed: 30022119
Mol Cell. 2012 Jul 27;47(2):320-9
pubmed: 22841003
Nat Commun. 2018 Sep 25;9(1):3925
pubmed: 30254264
EMBO J. 2010 Apr 21;29(8):1446-57
pubmed: 20360682
Nat Struct Mol Biol. 2016 Aug;23(8):714-21
pubmed: 27348077
Am J Cancer Res. 2018 Jan 01;8(1):39-55
pubmed: 29416919
Bioinformatics. 2010 Sep 1;26(17):2204-7
pubmed: 20639541
EMBO J. 1992 Feb;11(2):769-76
pubmed: 1311258
EMBO J. 2018 Sep 14;37(18):
pubmed: 30154076
Mol Cell. 2013 Mar 7;49(5):872-83
pubmed: 23333306
Nat Commun. 2020 Feb 12;11(1):857
pubmed: 32051414
Science. 2013 Feb 8;339(6120):711-5
pubmed: 23306439
Nat Commun. 2021 Aug 10;12(1):4843
pubmed: 34376693
Nature. 2018 Aug;560(7716):112-116
pubmed: 30022158
Nature. 2021 May;593(7859):440-444
pubmed: 33767446
Nature. 2018 Aug;560(7716):122-127
pubmed: 30046110
Nat Commun. 2019 Jan 8;10(1):87
pubmed: 30622252
Mol Cell. 2009 Oct 23;36(2):193-206
pubmed: 19854130
Cell. 2018 May 3;173(4):972-988.e23
pubmed: 29656893
J Biol Chem. 2013 Apr 19;288(16):11135-43
pubmed: 23486525
Mol Cell. 2019 Mar 21;73(6):1267-1281.e7
pubmed: 30704900
Biochemistry. 1991 Sep 3;30(35):8590-7
pubmed: 1909569
Cell. 2018 Aug 23;174(5):1127-1142.e19
pubmed: 30078706
Front Genet. 2013 Jun 03;4:99
pubmed: 23760669
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Genome Res. 2012 May;22(5):957-65
pubmed: 22367190
Comput Struct Biotechnol J. 2016 Apr 14;14:161-7
pubmed: 27239262
Mol Cell. 2013 Mar 7;49(5):858-71
pubmed: 23333305
Crit Rev Biochem Mol Biol. 2016 May-Jun;51(3):195-212
pubmed: 27098756
Nature. 2018 Aug;560(7716):117-121
pubmed: 30022168
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Bioorg Chem. 2020 Nov;104:104253
pubmed: 32920362
Science. 2013 Feb 8;339(6120):700-4
pubmed: 23306437
EMBO Rep. 2019 May;20(5):
pubmed: 30948458
Nat Struct Mol Biol. 2010 Jun;17(6):688-95
pubmed: 20453858
Cell. 2005 Sep 9;122(5):693-705
pubmed: 16143102
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Mol Cell. 2020 Jan 2;77(1):26-38.e7
pubmed: 31653568
Genes Dev. 2020 Jan 1;34(1-2):7-23
pubmed: 31896689
Biochemistry. 1997 Jul 15;36(28):8443-54
pubmed: 9214288
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325

Auteurs

Jacob Paiano (J)

Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Nicholas Zolnerowich (N)

Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Wei Wu (W)

Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Raphael Pavani (R)

Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Chen Wang (C)

Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.

Hongzhi Li (H)

Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.
Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.

Li Zheng (L)

Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.
Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.

Binghui Shen (B)

Department of Cancer Genetics and Epigenetics, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.
Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, California 91010, USA.

Barry P Sleckman (BP)

Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

Bo-Ruei Chen (BR)

Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

André Nussenzweig (A)

Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Articles similaires

DNA Glycosylases Nucleosomes Humans 8-Hydroxy-2'-Deoxyguanosine DNA Repair
Humans Ku Autoantigen Ataxia Telangiectasia Mutated Proteins Male DNA-Activated Protein Kinase
Animals Caenorhabditis elegans Caenorhabditis elegans Proteins Asymmetric Cell Division DNA Helicases

Chemoproteogenomic stratification of the missense variant cysteinome.

Heta Desai, Katrina H Andrews, Kristina V Bergersen et al.
1.00
Humans Mutation, Missense Cysteine Proteomics Proteome

Classifications MeSH